Bluejay Diagnostics is a clinical-stage company developing the Symphony platform designed to provide rapid IL-6 immunoassay testing for sepsis management in critical care. While its Symphony device demonstrates promising clinical utility potential, the company remains pre-commercial with no operating income and an accumulated deficit exceeding $40 million as of 2025. Bluejay aims for FDA 510(k) clearance by late 2027 but must navigate steep financial challenges, including a cash runway of just over $5 million and an urgent need to raise at least $20 million by year-end 2027 to sustain clinical trials and manufacturing upgrades necessary for regulatory submission. The firm has employed aggressive reverse stock splits and numerous warrants to comply with Nasdaq requirements and finance operations, complicating its capital structure and dilution risk profile.